Update on romiplostim therapy for immune thrombocytopenic purpura

Thrombopoietin mimetic is superior to standard of care in adults with immune thrombocytopenic purpura (ITP) and demonstrates activity and tolerability in pediatric ITP patients

May 25, 2011|The Journal of Community and Supportive Oncology

Matt Stenger, MS

FROM THE FEDERAL REGISTER

References

1. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010;363:1889–1899.
2. Elalfy MS, Abdelmaksoud AA, Eltonbary KY. Romiplostim in children with chronic refractory ITP: randomized placebo controlled study. Ann Hematol 2011;doi10.1007/s00277- 011-1172-9.
3. Buchanan GR, Bomgaars L, Bussel JB, et al. A randomized, double-blind, placebo-controlled phase 1/2 study to determine the safety and efficacy of romiplostim in children with chronic immune (idiopathic) thrombocytopenic purpura (ITP). Blood 2009;114(22):680.
4. Safety and efficacy study of AMG 531 to treat ITP in pediatric subjects. ClinicalTrials. gov Web site. https://clinicaltrials.gov/ct2/ show/NCT00515203. Accessed May 12, 2011.
5. A study evaluating the safety and efficacy of long-term dosing of romiplostim in thrombocytopenic pediatric subjects with immune (idiopathic) thrombocytopenia purpura. ClinicalTrials. gov Web site. https://clinicaltrials. gov/ct2/show/study/NCT01071954. Accessed May 12, 2011.